Heparan sulphate and dermatan sulphate have both antithrombotic and anticoagulant properties. These are, however, significantly weaker than those of a comparable amount of standard pig mucosal heparin. Antithrombotic and anticoagulant effects of glycosaminoglycans depend on their ability to catalyse the inhibition of thrombin and/or to inhibit the activation of prothrombin. Since heparan sulphate and dermatan sulphate are less sulphated than unfractionated heparin, we investigated whether the decreased sulphation contributes to the lower antithrombotic and anticoagulant activities compared with standard heparin. To do this, we compared the anticoagulant activities of heparan sulphate and dermatan sulphate with those of their derivatives resulphated in vitro. The ratio of sulphate to carboxylate in these resulphated heparan sulphate and dermatan sulphate derivatives was approximately twice that of the parent compounds and similar to that of standard heparin. Anticoagulant effects were assessed by determining (a) the catalytic effects of each glycosaminoglycan on the inhibition of thrombin added to plasma, and (b) the ability of each glycosaminoglycan to inhibit the activation of 125I-prothrombin in plasma. The least sulphated glycosaminoglycans were least able to catalyse the inhibition of thrombin added to plasma and to inhibit the activation of prothrombin. Furthermore, increasing the degree of sulphation improved the catalytic effects of glycosaminoglycans on the inhibition of thrombin by heparin cofactor II in plasma. The degree of sulphation therefore appears to be an important functional property that contributes significantly to the anticoagulant effects of the two glycosaminoglycans.
INTRODUCTION
The antithrombotic and anticoagulant activities of dermatan sulphate (DS) and heparan sulphate (HS) have been demonstrated previously (Grossman & Dorfmann, 1957; Kirk, 1959; Morrison et al., 1968; Izuka & Murata, 1972; Murata et al., 1975; Bjornsson et al., 1982; Buchanan et al., 1985; Ofosu et al., 1985 Ofosu et al., , 1986 . These activities are significantly weaker on a weight basis than those of unfractionated heparin. Anticoagulant and antithrombotic activities of glycosaminoglycans (GAGs) depend on their ability to catalyse thrombin inhibition and/or to inhibit prothrombin activation Ofosu et al., 1985 Ofosu et al., , 1987 . Approximately onethird of heparin molecules have a unique pentasaccharide sequence that results in the binding of these molecules of heparin to antithrombin III with high affinity (Hopwood et al., 1976; Rosenberg et al. 1978; Choay et al., 1983) . This high-affinity binding, which activates antithrombin III, is primarily responsible for the antithrombotic and anticoagulant effects of heparin. However, the fraction of heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal human plasma but much less effectively than does unfractionated heparin (Ofosu et al., 1982) . The low-affinity fraction also augments the antithrombotic effects of high-affinity oligosaccharides of heparin (Thomas et al., 1982) . Although HS possesses this pentasaccharide sequence, the proportion of HS chains with this sequence is significantly lower than that of heparin. DS lacks this pentasaccharide sequence (Lindahl & Hook, 1978; Casu, 1985) .
A second major difference between unfractionated heparin, HS and DS is that heparin is more sulphated than the others (Lindahl & Ho6k, 1978; Casu et al., 1983; Casu, 1985) . We therefore investigated whether the lower anticoagulant effects of DS and HS relative to that of pig mucosal heparin could be improved by chemical modification to increase their degree of sulphation.
MATERIALS AND METHODS Materials
Some properties of the seven GAGs used in the present study are summarized in Table 1 . The source and methods of preparation of these materials have been described previously (Johnson, 1982; Casu et al., 1983; Cerskus et al., 1984; Johnson, 1984; Johnson & Paterson, 1986) . HS type IIA (Johnson, 1984) and DS (sample 6) were sulphated in vitro by the following procedure. Resulphation of HS type IIA in vitro yielded HS-S listed in Table 1 . The GAG (0.5 g) was freeze-dried, covered with dry pyridine (0.8 ml), and SO3 solution (1 M in dimethylformamide, 5 ml) was then added. The mixture was heated at 60°C for 5 h with occasional shaking.
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889 Biochem. J. (1987) 248, 889-896 (Printed in Great Britain) (Cerskus et al., 1984) . The remainder are preparations isolated from heparin by-product materials (Johnson, 1982) . HS type I (sample 3) and HS type IIB (sample 5) are identical with HS I (also Hes A) and HS IIB (also Hes G) respectively, as previously described Johnson, 1984) . In all heparan sulphates, glucosamine accounted for 97 % or more of the total hexosamine (Johnson, 1984) . DS (sample 6), for which over 99 % of the total hexosamine was galactosamine and which was free of other GAGs by cellulose acetate electrophoresis, was isolated by the procedures of Johnson & Paterson (1986) . The sulphate/carboxylate ratio refers to the ratio of sulphate to carboxylate per disaccharide unit. This ratio was determined by conductimetric titration (Casu & Gennaro, 1975; Johnson, 1982 After decantation, the solid product was washed with dimethylformamide (2 x) and propan-2-ol (2 x), then dissolved in water, neutralized with NaOH and dialysed exhaustively against water. The molecular mass [by gelpermeation chromatography, by using the procedure of Johnson (1982) ] appeared to be essentially unaltered even though the degree of sulphation was increased substantially. The sulphate/carboxylate ratios were determined by the procedures of Casu & Gennaro (1975) and Johnson (1982) . It may be noted in Table 1 Factor IX concentrate (human) by using previously described procedures (Modi et al., 1984) . The prothrombin was labelled with Nal25I to an initial specific radioactivity of 5 x 106 c.p.m./#g (Tollefsen & Blank, 1981) . Factor X was activated with Factor X activator from Russell's-viper venom and freed of the activator by chromatography on DEAE-Sephadex (Ofosu et al., 1981) .
Effect of the GAGs on the inactivation of thrombin or Factor Xa by human plasma Previously described procedures were used to assess the effect of each of the seven GAGs listed in Table 1 on the inhibition of Factor Xa or thrombin by human plasma (Ofosu et al., 1984a (Ofosu et al., ,b, 1985 . Each inhibition reaction was carried out in defibrinated plasma that contained 10 mM-CaCl2 and human brain kephalin (6 ,g of organic phospholipid/ml of plasma) (Ofosu et al., 1981 (Ofosu et al., , 1984a . These additions facilitated direct comparison of the catalysis of the inhibition of the two proteinases and the inhibition of the generation of their activities under the same experimental conditions. Ca2' and coagulant phospholipids are known to influence the catalytic effect of heparin on the inhibition of Factor Xa and thrombin by antithrombin III (Marciniak, 1973; Walsh et al., 1974; Ofosu et al., 1984b) . The final dilution of plasma [after the addition of CaCl , kephalin, Factor Xa (20 nM) or thrombin (100 nM)], with or without an added GAG, was 1 in 2. The final concentration of the added GAG was 0.66, 6.6 or 66 jig/ml of incubation mixture. The defibrinated plasma and the suspension of Factor Xa (or thrombin), CaCl2, kephalin and the GAG under study were prewarmed separately at 37°C for 3 min before mixing. The inhibition reaction (the second incubation) was performed for 1 min at 37 'C, after which a sample was added to 9 vol. of the chromogenic substrate and the residual enzymic activity measured. Residual Factor Xa and thrombin were then determined (Ofosu et al., 1981 (Ofosu et al., , 1984a . 1987 890 Anticoagulant activities of heparan sulphate and dermatan sulphate APTT reagent (1 vol.) was added to the plasma (2 vol.). After an incubation of 3 min at 37°C, 1 vol. of 40 mM-CaCl2 that had been prewarmed to 37°C was added. The enzymically active thrombin and Factor Xa generated subsequently were determined quantitatively with S-2238 and S-2222 respectively (Ofosu et al., 1981 (Ofosu et al., , 1984a . To do this, a sample (1 vol.) was added to 4 vol. of 5 mM-EDTA kept at 4°C to stop further prothrombin activation. Then 1 vol. of this diluted plasma was added to 39 vol. of 0.25 mM-S-2238 (for thrombin determination) or 9 vol. of 0.4 mM-S-2222 (for Factor Xa determination) prewarmed to 37°C and the AA/min determined. The effects of each of the seven GAGs on the generation of thrombin and Factor Xa activities were also determined. The GAG was added to the contactactivated plasma simultaneously with the CaCl2. Three final concentrations of each GAG were used: 0.66,ug, 6.6 ,tg or 66 gg of GAG/ml of contact-activated plasma with re-added Ca2+. The appearance of thrombin activity, and its inhibition by each GAG, were determined 45 s, 60 s and 120 s after the re-addition of Ca2+. The appearance of Factor Xa activity, or its inhibition by a GAG, was determined 2 min after the re-addition of c2+.
Ca2P
athways for the inhibition of the generation of thrombin activity by glycosaminoglycans
In order to determine the pathways by which each GAG inhibits the appearance of thrombin activity in plasma, 125I-labelled human prothrombin was added to the plasma before contact activation and subsequent addition of CaCl2 to initiate the activation of prothrombin (Ofosu et al., 1986 (Ofosu et al., , 1987 . After the CaCl2 addition, samples of the contact-activated plasma were withdrawn 45 s and 60 s later and added to 4 vol. of 30 mM-sodium barbiturate buffer, pH 7.4, which also contained 5 mM-EDTA, 0.1 % bovine serum albumin, 1 /LM-Phe-Pro-Arg-CH2Cl and dansyl.Glu-Gly-ArgCH2Cl for 2 min at 37 'C. This buffer served to stop further activation of prothrombin and further inhibition of the thrombin formed by its plasma inhibitors. Prothrombin activation was assessed by the appearance of 1251I-prothrombin fragment 1 + 2 (F112) and 1251-thrombin after SDS/polyacrylamide-gel electrophoresis and autoradiography (Ofosu et al., 1987) . Catalysis of the inhibition of the thrombin activity generated in situ was assessed by the formation of 1251-thrombin-inhibitor complexes in plasma containing the GAG under study.
RESULTS

Catalytic effects of GAGs on the inhibition of thrombin and Factor Xa by plasma
The effects of the seven GAGs on the inhibition of the activities of thrombin and Factor Xa are summarized in Table 2 . Unfractionated heparin (sample 1) is the most active catalyst on the inhibition of the two proteinases at the lowest concentration of GAGs (0.66 ,ug/ml). Heparin with low affinity to antithrombin III (sample 2) is only as effective as DS and HS type I in catalysing thrombin inhibition. It is even less effective than HS type I in catalysing the inhibition of Factor Xa. Although the other GAGs are less active than unfractionated heparin in catalysing the inhibition of thrombin, further sulphation of an HS in vivo (i.e. the naturally occurring HS IIB) and resulphation of DS (in vitro) markedly increase their ability to enhance the inhibition of thrombin at the lowest concentration. It is evident that there are no great differences in performance, at 66 ,tg/ml, between any of unfractionated heparin, low-affinity heparin or the HS preparations (samples 1 to 5), whereas DS is a moderately effective catalyst for thrombin inhibition but has little effect on Factor Xa inhibition. Against Factor Xa, resulphation of DS in vitro increases its activity whereas sulphation in vitro of HS decreases its activity, in each case to a moderate extent. Effects of the degree of sulphation of GAGs on the formation of enzymicaliy active Factor Xa in contactactivated plasma Table 3 lists the effectiveness of the seven GAGs in inhibiting the appearance of enzymically active Factor Xa. None of the seven can completely inhibit the appearance of Factor Xa activity even at 66,ug/ml, a concentration that for heparin in vivo would be excessive. Heparin with low affinity to antithrombin III is less effective than any of the HS preparations in inhibiting the appearance of Factor Xa activity, suggesting that most of the inhibition seen with HS preparations is due Effects of the degree of sulphation on the appearance of enzymicalHy active thrombin in contact-activated plasma The appearance of enzymically active thrombin can be almost completely inhibited, at least at the highest concentration, by five of the seven GAGs, the remaining two being HS type I and DS, the least sulphated GAGs (Table 4) . Heparin is most active; the activity of heparin is probably attributable to the fraction with high affinity to antithrombin III, since the lowest concentration of heparin with low affinity to antithrombin III has little inhibitory effect. Also, the sulphation in vitro of HS and DS to heparin-like extents does not make these derivatives as active as unfractionated heparin, though for DS the increase in activity over that of the parent GAG is noteworthy. None of the HS preparations inhibited the generation of enzymically active thrombin at the lowest concentration as well as unfractionated heparin. HS IIB was the most effective of the three HS preparations. The low-sulphate preparation HS I was the least active; the resulphated preparation HS-S, with the highest sulphate content of the three preparations, had only marginally increased activity over that of HS I. Neither HS I nor HS-S achieved complete inhibition (i.e. 95 % or greater) even at the highest concentration used.
Another approach to comparing the effectiveness of the seven GAGs as anticoagulants is summarized in 3-5, 0.66,6 .6 and 66 sg of GAG/ml respectively. The time after re-addition of Ca 2+ was 45 s. For coding of products see Fig. 1 legend. ml of plasma (Fig. 3a, lane 5) , with HS type TIB it was observed at 6.6 and 66.0 psg/ml of plasma (Fig. 3b, lanes 4 and 5), and with HS-S inhibition of prothrombin activation was incomplete at any concentration (Fig. 3c) . Inhibition of prothrombin activation was complete only with 66 ,sg ofHS II/ml when the incubation was increased to 60 s. Incomplete inhibition of prothrombin activation was always accompanied by the formation of thrombin-antithrombin III and thrombin-a~2-macroglobulin complexes. HS-S also catalysed the formation of thrombin-heparin cofactor II complex.
The two higher concentrations of DS catalysed the inhibition of thrombin by heparin cofactor II (Fig. 4a,  lanes 4 and 5) . The highest concentration of DS also inhibited partially the activation of prothrombin 45 s after the re-addition of Ca 21 (Fig. 4a, lane 5) . In addition, no complexes of thrombin with antithrombin III or z2-macroglobulin were formed when the concentration of DS was 66.0 /sg/ml of plasma. DS-S was better able to inhibit the activation of the prothrombin than DS since complete inhibition of prothrombin activation was Vol. 248 0.66, 6.6 and 66 ,g of the GAG/ml of activated plasma.
For coding of products see Fig. 1 legend. Anticoagulant activities of heparan sulphate and dermatan sulphate 895 observed at the two higher concentrations of DS-S (Fig. 4b, lanes 4 and 5) .
DISCUSSION
The structures of the GAGs used in this work differ in a number of ways; the three major ones are (a) the constituent backbones, (b) the extent of sulphation and (c) molecular mass. The polysaccharide backbones differ, and among the seven samples there are three types of uronosylhexosamine backbones. The heparin-heparan class has hybrid iduronosyl/glucuronosyl-(l -*4)-glucosamine units, with mostly iduronosyl in heparins and with less iduronosyl in heparans. The glucosamine units are N-acetylated or N-sulphated. The iduronosyl residues in heparins and heparans (the latter in vivo) increase in parallel with increased sulphation, and ultimately an increase in the proportion of chains able to activate antithrombin III. Dermatans have, primarily, iduronosyl-(l -*3)-galactosamine (as N-acetylated) units (Lasker, 1977; Hook et al., 1984; Casu, 1985) . From Tables 2, 3, 4 and 5 it can be seen immediately that GAGs 1 and 4, which have the heparin/heparan backbone and are most sulphated in vivo, have the highest activity in all systems. The galactosaminoglycans, GAGs 6 and 7, show activities that are generally lower than those of unfractionated heparin (GAG 1) and HS type IIB (GAG 4). It is evident from Tables 2, 4 and 5 that in general the efficiency with which a GAG catalyses the inhibition of thrombin parallels its ability to inhibit the generation of enzymically active thrombin in plasma. Although at first glance this might indicate that the anticoagulant effects result strictly from the catalysis of the inhibition of the thrombin generated in situ, it is very likely that there is an additional contributory effect to anticoagulation. Specifically, some GAGS are better able to suppress the activation of prothrombin than others with similar catalytic effects on thrombin inhibition. The various effects of the seven GAGs support the concept that the ability to catalyse the inhibition of Factor Xa and/or its generation does not always translate directly into a similar effect on the generation of thrombin activity . This is best demonstrated by the N-acetylgalactosamine-containing GAGS 6 and 7. They are the least able to inhibit the appearance of Factor Xa activity, yet they catalyse the inhibition of thrombin and inhibit the generation of enzymically active thrombin.
A second major difference among the GAGs is the degree of sulphation, increased over that of the natural product in HS-S and DS-S by further sulphation in vitro. Sulphation, as already noted, correlates better with inhibition of the appearance of thrombin activity in contact-activated plasma than with other activities. However, it should be borne in mind that in natural GAGs changes in the extent of sulphation are always accompanied by other structural variations. In the heparin/heparan class increased sulphation is always accompanied by decreased glucuronate and increased iduronate content, and also by other sequence changes including decrease in N-acetylation in the hexosamine and an increase in the fraction that can activate antithrombin III (Lasker, 1977; Hook et al., 1984; Jacobson et al., 1984; Johnson, 1984; Casu, 1985) . The effects of resulphation in vitro of HS and DS on the appearance of thrombin activity, and the similarity of their effects to that of heparin with low affinity to antithrombin III, suggest that the sulphation of GAGs with predominantly iduronosyl residues yields products better able to inhibit the generation of thrombin activity than sulphation of GAGs with predominantly glycuronosyl residues. Heparin with low affinity to antithrombin III and DS-S, both likely to have iduronate as the predominant uronic acid, are better inhibitors of thrombin generation than HS-S, which probably has more glucuronate than the iduronate content.
The seven GAGs inhibit the generation of thrombin activity in plasma by a variety of ways. Heparin completely inhibits the activation of prothrombin. This is probably due to the fraction with high affinity to antithrombin III, as the activity of heparin with low affinity to antithrombin III is approx. 10 % that of unfractionated heparin. Low concentrations of natural forms of HS inhibit the generation of thrombin activity by catalysing the inhibition of the thrombin generated in situ by antithrombin III (Fig. 3) . Increased sulphation as found in HS type IIB, which in vivo makes the HS more heparin-like, also improves its ability to inhibit the activation of prothrombin. Increased sulphation as such, without an accompanying increase in the ability to activate antithrombin III (i.e. sulphation in vitro), does not improve the ability of HS to inhibit the activation of prothrombin (Tables 4 and 5 and Fig. 3) .
The major anticoagulant effect of DS is the catalysis of the inhibition of thrombin generated in situ by heparin cofactor II (Fig. 4) . Unlike HS, increased sulphation in vitro also increases the ability of DS to inhibit prothrombin activation directly. Thus sulphation of the DS in vitro confers on the new product properties similar to those of heparin with low affinity to antithrombin III (Table 5 ) and pentosan polysulphate (Ofosu et al., 1986 (Ofosu et al., , 1987 . Unlike HS, resulphated DS is also better able to accelerate the thrombin inhibition than is the parent DS (Table 2 ). These results suggest that the extent of sulphation of HS and DS in vivo may influence their ability to inhibit the activation of prothrombin and to catalyse the inhibition of thrombin. Alterations in the sulphation pattems of HS and DS may be an important contributory factor to the evolution of thrombosis in vivo. The extent to which sulphation of vessel-wall glycosaminoglycans varies within the vasculature may be an important factor in the pathogenesis of thromboembolic events.
